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Dominant-negative AT2 receptor oligomers induce G-protein
arrest and symptoms of neurodegeneration
Abstract
Neurodegeneration in Alzheimer;s disease (AD) correlates with dysfunction of signaling mediated by
Gaq/11. Non-dissociable angiotensin II AT2 receptor oligomers are linked to the impaired
Gaq/11-stimulated signaling of AD patients and transgenic mice with AD-like symptoms. To further
analyze the role of AT2 receptor oligomers, we induced the formation AT2 oligomers in an in vitro cell
system. Similarly as in vivo, sequential oxidative and transglutaminase-dependent cross-linking steps
triggered the formation of AT2 oligomers in vitro. Elevated reactive oxygen species mediated oxidative
cross-linking of AT2 monomers to dimers involving tyrosine residues located at putative inter-receptor
contact sites of the cytoplasmic loop connecting transmembrane helices III/IV. Cross-linked AT2 dimers
were subsequently a substrate of activated transglutaminase-2, which targeted the carboxyl terminus of
AT2 dimers as assessed by truncated and chimeric AT2 receptors, respectively. AT2 oligomers acted as
dominant-negative receptors in vitro by mediating Gaq/11 protein sequestration and Gaq/11 protein
arrest. The formation of AT2 oligomers and G-protein dysfunction could be suppressed in vitro and in
vivo by an AT2 receptor mutant. Inhibition of AT2 oligomerization upon stereotactic expression of the
AT2 receptor mutant revealed that Gaq/11-sequestering AT2 oligomers enhanced the development of
neurodegenerative symptoms in the hippocampus of transgenic mice with AD-like pathology. Thus,
AT2 oligomers inducing Gaq/11 arrest are causally involved in inducing symptoms of
neurodegeneration.
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Neurodegeneration in Alzheimer`s disease 
(AD*) correlates with dysfunction of 
signaling mediated by Gαq/11. Non-
dissociable angiotensin II AT2 receptor 
oligomers are linked to the impaired Gαq/11-
stimulated signaling of AD patients and 
transgenic mice with AD-like symptoms. To 
further analyze the role of AT2 receptor 
oligomers, we induced the formation AT2 
oligomers in an in vitro cell system. 
Similarly as in vivo, sequential oxidative and 
transglutaminase-dependent cross-linking 
steps triggered the formation of AT2 
oligomers in vitro. Elevated reactive oxygen 
species mediated oxidative cross-linking of 
AT2 monomers to dimers involving tyrosine 
residues located at putative inter-receptor 
contact sites of the cytoplasmic loop 
connecting transmembrane helices III/IV. 
Cross-linked AT2 dimers were subsequently 
a substrate of activated transglutaminase-2, 
which targeted the carboxyl terminus of 
AT2 dimers as assessed by truncated and 
chimeric AT2 receptors, respectively. AT2 
oligomers acted as dominant-negative 
receptors in vitro by mediating Gαq/11 
protein sequestration and Gαq/11 protein 
arrest. The formation of AT2 oligomers and 
G-protein dysfunction could be suppressed 
in vitro and in vivo by an AT2 receptor 
mutant. Inhibition of AT2 oligomerization 
upon stereotactic expression of the AT2 
receptor mutant revealed that Gαq/11-
sequestering AT2 oligomers enhanced the 
development of neurodegenerative 
symptoms in the hippocampus of transgenic 
mice with AD-like pathology. Thus, AT2 
oligomers inducing Gαq/11 arrest are 
causally involved in inducing symptoms of 
neurodegeneration. 
 
Dysfunction of Gαq/11 is a characteristic feature 
of AD patients and transgenic mice with AD-
like symptoms (see accompanying manuscript 
and references 1-5). The Gαq/11-protein defect 
is a well-established hallmark of clinicial AD 
(5). However, the pathophysiological role of 
the G-protein defect is barely understood. A 
direct relationship between Gαq/11 dysfunction 
and the pathogenesis of AD leading to 
neurodegeneration and dementia is suggested 
by the important role of Gαq/11 proteins in 
neuronal survival and memory (6,7). In 
addition, many of the cognition-enhancing 
effects of acetylcholine are mediated by the 
Gαq/11-coupled muscarinic receptors (8). The 
M1 receptor is a major target of Gαq/11 
dysfunction of AD patients and mice, and 
impaired Gαq/11-coupling of M1 receptors 
correlates with disease severity (5).  
To better understand the 
pathophysiological function of the G-protein 
defect in AD, we analyzed the mechanism 
accounting for the G-protein defect in AD. In 
the first manuscript we identified cross-linked 
AT2 receptor oligomers in brain of AD patients 
and transgenic mice with AD-like symptoms. 
Co-enrichment studies showed that AT2 
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 2 
receptor oligomers resembled dominant-
negative receptors by sequestering Gαq/11 in 
the absence of agonist. The cross-linked AT2 
receptors were directly linked to the 
progression of AD because (aggregated) 
amyloid β (Aβ) triggered AT2 oligomerization 
in vivo in a dose-dependent manner by a two-
step process of oxidative and transglutaminase-
dependent cross-linking. Down-regulation of 
AT2 receptors by RNA interference revealed 
that AT2 receptor (oligomers) contributed to 
Gαq/11 dysfunction of transgenic mice with 
AD-like symptoms. Specifically, AT2 receptor 
oligomers impaired signaling of Gαq/11-
coupled muscarinic M1 receptors in the 
hippocampus. 
Because activation of hippocampal 
Gαq/11-stimulated signaling retards the 
development of AD-like symptoms in 
transgenic mice (9), we thought that AT2 
receptor oligomers were directly involved in 
symptoms of neurodegeneration. To address 
this question we used an AT2 receptor mutant 
to suppress AT2 oligomerization in vitro and in 
vivo. We present here that inhibition of AT2 
oligomerization by stereotactic expression of a 
mutated AT2 receptor retarded the 
development of neurodegenerative symptoms 
in the hippocampus of transgenic mice with 
AD-like pathology. These observations 
provide strong evidence for an involvement of 
AT2 oligomers in mediating symptoms of 
neurodegeneration. 
  
EXPERIMENTAL PROCEDURES 
 
Cell culture, protein expression and functional 
assays- Cultivation of human embryonic 
kidney (HEK) cells, and transfection with 
plasmids encoding AT2, AT2ΔCTer, M1, 
Gα11Q209L, or transglutaminase-2 under control 
of the CMV promoter was performed as 
described (10,11). Reactive oxygen species 
(ROS) was induced by expression of NOX-3. 
Changes in total inositol phosphates and 
measurement of [Ca2+]i were determined with 
intact cells (11,12). Basal and stimulated 
binding of [35S]GTPγS (specific activity 1250 
Ci/mmol; final concentration 0.5 nM) to Gαq/11 
was determined in the presence of 0.1 µM 
GDP in a volume of 200 µl in triplicates with 
membranes (25 µg protein/point) prepared 
from cells and mouse hippocampal tissue 
followed by immuno-affinity enrichment of 
Gαq/11. The method measures specifically the 
activation of Gαq/11 because the applied 
antibodies cross-react specifically with Gαq/11 
as determined in immunoblot. 
Transglutaminase activity was determined by a 
[3H]putrescine incorporation assay (11). 
Immuno-affinity enrichment of Gαq/11 
followed by immunoblot detection of co-
enriched AT2 was performed by a method that 
was described (12). 
Quantification of the carbachol-
stimulated M1-Gαq interaction in the presence 
of increasing levels of oligomeric AT2 (0 - 300 
fmol/mg protein) was performed after 
immuno-affinity enrichment of M1 receptors 
from M1 receptor-expressing HEK cells (~900 
fmol/mg protein) co-expressing oligomeric 
AT2 as indicated. Briefly, HEK cell 
membranes (50 µg/point) in GTP-free buffer 
supplemented with 2 mM MgCl2 were 
incubated in the absence or presence of 1 mM 
carbachol for 60 min at 12 °C followed by 20 
min at 24 °C and the addition of 1 mM DSP. 
Membranes were washed three times with 20 
mM Tris (pH 7.5) supplemented with 1 mM 
EDTA and protease inhibitors, collected by 
centrifugation and solubilized in 200 µl buffer 
(1 % deoxycholate, 0.1 % NP40, 0.1 % SDS in 
20 mM Tris, pH 7.4 supplemented with 
protease inhibitors). The solubilisate was 
incubated for 2 h at 4 °C with an immuno-
affinity matrix of M1-specific antibodies 
coupled to Affigel 10. After washing, Gαq co-
enriched with the M1 receptor was quantified 
by addition of [125I]-labeled F(ab)2 fragments 
of immunoselected anti-Gαq antibodies (1 x 
10-8 M, specific activity ~0.02 Ci/mg) to the 
affinity matrix. After 2 h of incubation at 4 °C, 
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the affinity matrix was washed three times 
with ice cold buffer, and radioactivity was 
determined in a γ-counter. To determine the 
carbachol-stimulated M1-Gαq interaction, 
bound radioactivity in the absence of carbachol 
(<10 %) was subtracted. In a parallel approach, 
Gαq co-enriched with the M1 receptor was 
quantified in immunoblot with Gαq-specific 
antibodies after elution from the affinity matrix 
and SDS-PAGE under reducing conditions. 
Activities of α-secretase present in 
hippocampal tissue of 13-month-old stressed 
APPSw mice were determined using a 
commercially available kit (R&D Systems). 
Antibodies for immunoblotting and 
immunohistochemistry- The following 
antibodies were used for immunoblotting, 
affinity purification and immuno-
histochemistry (10-12): affinity-purified 
rabbit/rat polyclonal anti-AT2 antibodies  
(raised against an antigen encompassing amino 
acids 320-349 of the human AT2 receptor); 
affinity-purified rabbit polyclonal anti-AT2 
antibodies  (raised against an antigen 
encompassing amino acids 326-349 of the 
human AT2 receptor); affinity-purified rabbit 
polyclonal anti-AT2 antibodies  (raised against 
an antigen encompassing amino acids 16-35 of 
the human or mouse AT2 receptor); affinity-
purified rabbit/rat polyclonal anti-M1 
antibodies  (raised against an antigen 
encompassing amino acids 231-350 of the 
human M1 receptor); affinity-purified rabbit 
polyclonal anti-transglutaminase antibodies  
(raised against an antigen encompassing amino 
acids 1-20 of mouse transglutaminase-2); 
affinity-purified rabbit polyclonal anti-Gαq/11 
antibodies  (raised against the C-terminus of 
Gαq/11). Immunoblotting and 
immunohistochemistry were routinely used to 
determine and confirm cross-reactivity of the 
antibodies with the respective proteins (10-12) 
Protein detection in immunoblot- Membranes 
were prepared by sucrose density gradient 
centrifugation at 4 °C followed by partial 
enrichment (see accompanying manuscript). 
For immunoblotting analysis, protein samples 
were separated by SDS-PAGE under reducing 
conditions and supplemented with urea 
followed by transfer to PVDF membranes as 
described (11). Affinity-purified antibodies or 
F(ab)2 fragments of the respective antibodies 
pre-absorbed to human and mouse proteins, 
respectively, were used for detection of AT2, 
AT1 receptors, and Gαq/11. Applied antibodies 
were characterized in previous studies (first 
manuscript and references 10-13). Bound 
antibody was visualized by pre-absorbed 
F(ab)2 fragments of enzyme-coupled secondary 
antibodies or by enzyme-coupled Protein A 
followed by enhanced chemiluminescence 
detection (ECL plus). 
Fluorescence-activated cell sorting (FACS) 
analysis- Cell surface M1 receptors of 
transfected HEK cells were determined by 
FACS analysis using affinity-purified M1-
specific antibodies raised against an epitope 
corresponding to the receptor`s amino terminal 
region according to standard methods (11). 
Transgenic animals- Transgenic mice used in 
this study express human APP695 with the 
double mutation (K670N, M671L; APPSw), 
which was identified in a Swedish family with 
early onset Alzheimer`s disease (14). 
Lentiviral vector production- Vector plasmids 
were constructed for the production of third-
generation lentiviruses expressing wild-type 
AT2, and AT2ΔCTer under control of the CMV 
promoter. The generation of viral particles 
pseudotyped with the vesicular stomatitis virus 
G glycoprotein was described in the first 
manuscript. For stereotactic injection in mice, 
high titer lentiviral stocks were used (> 1x107 
transduction units/µl). 
Immunohistochemistry- For immuno-
histochemistry, paraffin-embedded sections (8 
µm, taken at 50 µm intervals for analyses, 10-
15 sections per set) were deparaffinized 
followed by antigen retrieval (11). 
Immunohistochemical staining of AT2 receptor 
was performed with F(ab)2 fragments of pre-
absorbed affinity-purified polyclonal 
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antibodies (10,11). Immunohistochemistry 
with antibodies to microtubule-associated 
protein 2 (MAP2) was used as a marker of 
neuronal cell bodies and dendrites (anti-MAP2 
antibodies, Sigma). DNA strand breaks were 
determined in situ applying TUNEL 
technology (Roche). All sections were imaged 
with a Leica DMI6000 microscope equipped 
with a DFC420 camera.  
Cerebral injection of lentiviruses- To inhibit 
the formation of cross-linked AT2 oligomers, 
lentivirus preparations encoding AT2ΔCTer were 
injected bilaterally into the CA1 area of 12 
month-old APPSw mice similarly as described 
in the first manuscript (anteroposterior -1.6 to -
2.3; lateral 1; dorsoventral -1.8). The control 
group received injection of a control lentivirus 
encoding β-galactosidase or wild-type AT2 
receptor. After 1 week of recovery, mice were 
subjected to the stress paradigm for 4 weeks. 
Five weeks after the lentiviral injection, 
behavioral analysis, biochemical analysis and 
immunohistochemistry were performed. 
Protein expression levels of lentivirus-
driven expression were routinely monitored in 
immunoblot with anti-AT2 receptor antibodies 
(~1.8- to 2.3- fold hippocampal over-
expression compared to mice injected with a 
control lentivirus encoding β-galactosidase). 
Induction of stress- The generation of Aβ was 
enhanced in 12-month-old APPSw mice by four 
weeks of stress as described in the first 
manuscript. Stressed mice with a significant 
decrease in sucrose preference (≤ 50% of 
sucrose consumption compared to non-stressed 
controls) were included in the study. After 28 
days of stress, 4h before beginning of the dark 
phase, brains from stressed and non-stressed 
APPSw mice were removed and processed for 
immunoblotting, functional studies, and 
immunohistochemistry as described above. 
Behavioral studies- We used the standard 
water maze task (hidden platform) to test for 
spatial memory (15). Testing involved four 
trials per day over 10 days starting after the 
stress period. On the day following the 10 days 
of acquisition testing, memory retention was 
determined in a single 60-s probe trial for 
which the submerged platform was removed 
(16). 
Animal experiments were reviewed 
and approved by the committees on animal 
research at the Universities of Hamburg and 
Cairo, and were conducted in accordance with 
the NIH guidelines. 
Statistics- Unless otherwise stated, data are 
expressed as mean ± s.e.m. To determine 
significance between two groups, we made 
comparisons using the unpaired two-tailed 
Student`s t-test. P values < 0.05 were 
considered significant. 
 
RESULTS 
 
 Oxidative and transglutaminase-
mediated cross-linking of AT2 receptors in 
vitro. In the first manuscript we have shown 
that (aggregated) Aβ induces the formation of 
AT2 receptor oligomers in vivo in a dose-
dependent manner. The formation of AT2 
oligomers in vivo is due to a two-step process 
of oxidative and transglutaminase-mediated 
cross-linking. To analyze whether reactive 
oxygen species (ROS) and transglutaminase 
were indeed sufficient to support the formation 
of AT2 oligomers, we reconstituted the cross-
linking in a non-neuronal in vitro system. For 
detection of AT2 receptors in immunoblot we 
applied AT2-specific antibodies cross-reacting 
specifically with the AT2 receptor of ~65±5 K 
of AT2 receptor-transfected HEK cells (cf. 
accompanying manuscript; Fig.1). Oxidization 
of AT2 receptor monomers of ~65 K  could be 
induced in HEK cells expressing NOX-3 as a 
ROS-generating system leading to the 
appearance of an SDS-stable dimeric AT2 form 
of ~130 K (Fig. 1A, lane 1). NOX-3 was 
chosen as a constitutively active ROS-
generating NADPH oxidase that also shows 
increased expression in AD patients (17). 
Cross-linking of AT2 receptors in NOX-3-
expressing HEK cells was suppressed by pre-
 at H
auptbibliothek Universitaet Zuerich Irchel. Bereich Forschung, on February 3, 2010
w
w
w
.jbc.org
D
ow
nloaded from
 
 5 
treatment with the antioxidant 
diferuloylmethane confirming involvement of 
ROS (Fig. 1A, lane 2).  
 ROS targets tyrosine residues of 
proteins leading to di-tyrosine formation. 
Tyrosine residues of AT2 are located at 
putative inter-receptor contact sites, i.e. the 
cytoplasmic loop connecting transmembrane 
helices III/IV (18). Those inter-receptor 
contact sites appear crucial for ROS-mediated 
cross-linking of AT2 because oxidative cross-
linking was strongly diminished in a mutated 
AT2 receptor lacking three tyrosines of 
connecting loop III-IV, AT2TyrAla143,148,162 (Fig. 
1B versus 1A). 
ROS-dependent cross-linking 
assembled AT2 for transglutaminase-mediated 
cross-linking because the concomitant action 
of ROS and transglutaminase-2 led to AT2 
receptor oligomers, whereas inhibition of 
transglutaminase-2 by monodansyl cadaverine 
prevented only the appearance of AT2 
oligomers but left the oxidized AT2 dimers 
intact (Fig. 1C). Thus, transglutaminase 
targeted AT2 receptors pre-assembled by 
oxidative cross-linking.  
Transglutaminase-dependent cross-
linking of oxidized AT2 receptors seemed to 
require the receptor`s carboxyl-terminus 
because a mutated AT2 receptor, AT2ΔCTer, 
lacking the carboxyl terminus was not 
significantly cross-linked by transglutaminase-
2, although oxidative dimerization was evident 
(Fig. 1D). This finding is in agreement with a 
model of receptor oligomers identifying C-
terminal residues as contact sites between 
dimers (18). 
ROS/transglutaminase targeted 
specifically the AT2 receptor because the 
related AT1 receptor appeared as a pure 
monomer under similar cross-linking 
conditions (Fig. 1E). The specificity of 
transglutaminase for oxidized AT2 receptor 
dimers was further analyzed by a chimeric AT2 
receptor with the carboxyl terminus of AT1. 
The chimeric AT2 receptor, AT2/AT1COO-, was 
not significantly cross-linked to oligomers by 
concomitant ROS/transglutaminase action, 
although (oxidized) AT2/AT1COO- dimers were 
detected in the presence of the 
transglutaminase inhibitor (Fig. 1F). This 
observation further confirms that the carboxyl 
terminus of the AT2 receptor is required for 
transglutaminase-dependent cross-linking of 
(oxidized) AT2 receptor dimers. 
Altogether, a two-step process of 
oxidative and transglutaminase-dependent 
cross-linking leads to AT2 oligomers in vitro 
(this manuscript) and in vivo (first manuscript). 
 AT2 receptor oligomers sequester 
Gαq/11 in vitro. The biochemical similarity 
between in vitro formed AT2 oligomers and in 
vivo detected AT2 oligomers was further 
analyzed. Similarly to AD patients and mice, 
AT2 oligomers of HEK cells sequestered 
Gαq/11 as determined by co-enrichment with 
Gαq/11 proteins while AT2 monomers/dimers 
did not significantly interact with Gαq/11 (Fig. 
2A, lanes 2,4 versus 1,3; and Fig. 2B).  
The interaction with an activated G-
protein-coupled receptor is an essential part of 
the G-protein activation step. In agreement 
with this paradigm, stimulation of muscarinic 
M1 receptors by carbachol strongly enhanced 
the interaction of M1 receptors with Gαq as 
determined by co-enrichment (Fig. 2C). The 
presence of AT2 oligomers prevented the 
carbachol-stimulated M1/Gαq interaction 
almost entirely (Fig. 2C). Thus, oligomeric 
AT2 is capable to suppress the interaction of 
Gαq with an activated heterologous receptor as 
would be expected from its Gαq/11-sequestering 
capacity. 
Next, we quantified the carbachol-
stimulated interaction of Gαq with the M1 
receptor (~900 fmol/mg) in the presence of 
increasing levels of AT2 oligomers. We chose 
the Gαq/11-coupled muscarinic M1 receptor 
because impaired G-protein coupling of M1 
correlates with disease severity in AD (5). 
Cross-linked AT2 oligomers potently inhibited 
the stimulated M1-Gαq interaction in a 
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concentration-dependent manner with an EC50 
of ~30 fmol/mg protein (Fig. 2D). As a 
control, comparable levels of the AT2ΔCTer 
mutant that was not cross-linked to oligomers 
under similar conditions (cf. Fig. 1D) had no 
significant effect on the carbachol-stimulated 
M1-Gαq interaction (Fig. 2E). These 
observations strongly indicate that 
physiological AT2 receptor expression levels 
of AD brain are sufficient to exert major 
effects on the interaction of G(α)q/11 with 
activated receptors (43.4 ± 2.7 fmol AT2/mg 
protein ± s.e.m., n=10, as determined with 
[125I]-labeled AT2 receptor-specific antibodies 
on prefrontal cortex membranes isolated from 
AD patients). 
 Gαq/11-sequestering AT2 receptor 
oligomers inhibit basal and carbachol-
stimulated activation of Gαq/11. The AT2 
oligomer-mediated sequestration of Gαq/11 
proteins was accompanied by reduced Gαq/11 
activation either under basal conditions or 
upon carbachol stimulation (Fig. 3A), whereas 
the AT2ΔCTer mutant that is not cross-linked to 
oligomers did not significantly affect the M1 
receptor-stimulated signal under similar 
conditions (Fig. 3B). 
 AT2 receptor oligomers suppress 
Gαq/11-stimulated signaling. We analyzed the 
effect of AT2 oligomers on Gαq/11-stimulated 
signaling in intact cells by measuring the 
Gαq/11-stimulated activation of phospholipases 
C. AT2 oligomers led to a strongly decreased 
inositol phosphate signal generation either 
under basal conditions or upon carbachol 
stimulation of transfected muscarinic M1 
receptors (Fig. 4A). Inhibition of M1 receptor-
stimulated signaling by AT2 oligomers was 
confirmed by significantly reduced potency 
and efficacy of carbachol (Fig. 4B). As a 
control, ROS and transglutaminase did not 
significantly affect M1-stimulated signaling in 
the absence of AT2 under similar conditions 
(data not shown). Cell surface M1 receptor 
levels as determined by fluorescence-activated 
cell sorting analysis with M1-specific 
antibodies were similar of HEK cells 
expressing dissociable AT2 receptors or cross-
linked AT2 oligomers (Fig. 4D, panel 1 versus 
2). 
 Signaling stimulated by direct 
activation of G-proteins with GTPγS or AlF4- 
was also strongly decreased in the presence of 
cross-linked AT2 oligomers while G-protein-
independent inositol phosphate generation 
triggered by direct activation of 
phospholipases C with calcium was not 
changed (Fig. 4A). These findings show that 
AT2 oligomers inhibit Gαq/11-stimulated 
signaling.  
 AT2 oligomers arrest constitutively 
activated Gα11Q209L. AT2 oligomers also 
interacted with a constitutively active mutant 
of Gα11, Gα11Q209L, and suppressed the inositol 
phosphate signal stimulated by this mutant 
(Fig. 4A). This observation reveals that AT2 
oligomers act in a dominant-negative manner 
and induce the virtual arrest of an activated 
Gαq/11 protein. The dominant-negative activity 
of the non-dissociable oligomeric AT2 receptor 
platform could account for the potent 
inhibition of Gαq/11-stimulated signaling at the 
cell membrane which is dependent on the 
release of a limited number of activated Gαq/11 
proteins triggered by stimulation of specific 
receptors. 
 Inhibition of calcium signaling and 
desensitization by AT2 oligomers. Impaired M1 
receptor-stimulated Gαq/11-protein activation in 
the presence of AT2 oligomers was also 
reflected by a decreased rise in the intracellular 
free calcium concentration, [Ca2+]i (Fig. 4C, 
panels 1,2 versus 4,5). The Gαq/11 inhibitory 
effect of the cross-linked AT2 oligomers was 
independent of the activation of AT2 by 
angiotensin II (Fig. 4C, panels 4,5). 
Activated G-proteins trigger signal 
generation as well as signal desensitization. To 
determine whether AT2 oligomers inhibited the 
desensitization of the M1 receptor, we 
pretreated the cells with carbachol. Carbachol 
pretreatment led to a significant decrease of the 
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M1-stimulated rise in [Ca2+]i on cells 
expressing dissociable AT2 receptors indicative 
of M1 receptor desensitization (Fig. 4C, panel 
3 versus 1,2). In contrast, the pretreatment with 
carbachol did not markedly decrease the M1 
signal on cells expressing oligomeric AT2 
receptors (Fig. 4C, panel 6 versus 4,5). Thus, 
AT2 oligomers inhibit signal generation and 
desensitization of the Gαq/11-coupled M1 
receptor. 
 Receptor desensitization is followed 
by receptor redistribution. Stimulation with 
carbachol induced prominent M1 receptor 
redistribution/internalization on cells 
expressing dissociable AT2 receptors (Fig. 4D, 
panel 3 versus 1). In contrast, inhibition of 
Gαq/11 proteins by AT2 oligomers led to a 
significantly reduced carbachol-stimulated M1 
receptor redistribution (Fig. 4D, panel 4 versus 
2). Together these findings show that cross-
linked AT2 oligomers arrest Gαq/11-stimulated 
signaling as reflected by inhibition of different 
signal transduction events triggered by a 
prototypic Gαq/11-coupled receptor, i.e. the 
muscarinic M1 receptor. 
 The truncated AT2ΔCTer mutant 
suppresses AT2 oligomerization in vitro and in 
vivo. We further assessed the impact of AT2 
oligomers on Gαq/11 activity and applied the 
truncated AT2ΔCTer mutant to interfere with AT2 
oligomerization. The AT2ΔCTer receptor when 
co-expressed with wild-type AT2 prevented the 
transglutaminase-dependent cross-linking step 
accounting for AT2 dimer/oligomer transition 
as determined in immunoblot with AT2-
specific antibodies detecting specifically wild-
type AT2 receptors (Fig. 5A). Upon inhibition 
of AT2 oligomerization, the basal and M1 
receptor-stimulated Gαq/11 activation were not 
significantly impaired by AT2 even in the 
presence of ROS and activated 
transglutaminase (Fig. 5B and cf. Fig. 3A). 
These findings confirm that AT2 oligomers 
prevent Gαq/11 activation. 
To suppress Aβ-induced AT2 
oligomerization in vivo we expressed the 
AT2ΔCTer mutant - that prevented AT2 
oligomerization in vitro - in the hippocampal 
CA1 area of stressed APPSw mice by 
stereotactic injection of a lentivirus. Similarly 
as in HEK cells, expression of AT2ΔCTer led to a 
marked decrease of AT2 oligomerization in the 
hippocampus of treated "AD mice" as 
determined by immunoblotting (Fig. 6A). 
Thus, AT2ΔCTer interfered with 
transglutaminase-mediated cross-linking of 
AT2 receptors in vitro and in vivo.  
 Inhibition of AT2 oligomerization 
slows progression of neurodegeneration in 
"AD mice". Detection of the endogenous AT2 
receptor and the transduced AT2ΔCTer by 
immuno-histochemistry revealed prominent 
neuritic/dendritic AT2 staining in a 
representative treated "AD mouse" expressing 
AT2ΔCTer that was not visible in the control, i.e. 
a representative APPSw mouse with stress-
enhanced Aβ generation and injection of a 
control lentivirus (Fig. 6B). Notably, there was 
prominent neuritic/dendritic AT2 staining in 
treated "AD mice" expressing AT2ΔCTer that 
was not visible in the controls (Fig. 6B). 
Immuno-histochemistry applying MAP2-
specific antibodies confirmed this observation 
and revealed largely intact neurites/dendrites in 
the injected CA1 area of mice expressing 
AT2ΔCTer, whereas there was extensive 
neuritic/dendritic degeneration in the control 
mice (Fig. 6C and cf. Fig. 7A). These findings 
strongly suggest that the AT2ΔCTer mutant 
retarded the development of neurodegenerative 
symptoms in stressed APPSw mice (Fig. 6C). 
 In accordance with these observations, 
TUNEL-positive cells were barely detectable 
in the injected CA1 area of treated "AD mice" 
expressing AT2ΔCTer, while CA1 neurons of 
control mice showed prominent TUNEL 
labeling (Fig. 6D, right versus left panel). 
Decreased symptoms of neuronal degeneration 
correlated with significantly reduced 
hippocampal transglutaminase activity (Fig. 
6E). 
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Treated "AD mice" expressing 
AT2ΔCTer also displayed a marginally better 
performance in the CA1-dependent learning 
task of spatial memory acquisition and 
retention compared to control "AD mice" with 
a high load of cross-linked AT2 receptor 
oligomers (Fig. 6F, G). Together these findings 
strongly suggest that inhibition of AT2 
oligomerization by expression of a protein 
inhibitor, i.e. the AT2ΔCTer mutant, retarded the 
development of neurodegenerative symptoms 
in stressed APPSw mice. 
Inhibition of AT2 oligomerization 
prevents G-protein dysfunction in "AD mice". 
Over-expression of wild-type AT2 receptors in 
"AD mice" further confirmed the involvement 
of AT2 receptor(s) (oligomers) in the 
neurodegenerative process. While 
immunohistochemistry revealed intact neurons 
in the CA1 area of mice with AT2ΔCTer-
dependent inhibition of oligomerization, there 
was profound dendritic pathology in CA1 
neurons of stressed APPSw mice over-
expressing comparable levels of 
oligomerization-prone wild-type AT2 receptors 
(Fig. 7A). Concomitantly, over-expression of 
AT2 (oligomers) led to strongly impaired M1 
receptor signaling compared to the prominent 
activation of Gαq/11 in mice expressing similar 
levels of AT2ΔCTer (Fig. 7B). These findings 
further confirm that AT2 (oligomers) induce 
Gαq/11 impairment whereas inhibition of AT2 
oligomerization by AT2ΔCTer prevents the 
development of G-protein dysfunction in 
transgenic mice with AD-like symptoms.  
In agreement with a role of M1 in non-
amyloidogenic processing of APP (19,20), 
dysfunctional M1 receptor-stimulated G-
protein activation of AT2 receptor expressing 
mice was accompanied by a marginally 
decreased hippocampal α-secretase activity 
compared to mice with expression of AT2ΔCTer 
and intact M1-stimulated signaling (Fig. 7C). 
Thus, the α-secretase activity of AD mice was 
preserved upon inhibition of AT2 
oligomerization by expression of an AT2 
mutant (this manuscript), and also upon down-
regulation of AT2 (oligomerization) by RNA 
interference (cf. first manuscript, Fig. 6). 
Altogether, the experiments reveal that 
targeting of AT2 receptor oligomers by 
expression of a protein inhibitor is feasible, 
and slows the development of 
neurodegenerative symptoms in transgenic 
mice with AD-like pathology. 
 
DISCUSSION 
 
G-protein dysfunction in brain of AD patients 
is a characteristic hallmark of clinical AD with 
neurodegeneration (5). In the first manuscript, 
G-protein dysfunction was linked to AT2 
oligomers that form in brain of AD patients 
and mice with AD-like symptoms. AT2 
receptor oligomers assemble in vivo by a two-
step process of oxidative and transglutaminase-
dependent cross-linking, which is triggered 
consecutively by (aggregated) Aβ in a dose-
dependent manner (see first manuscript). To 
further characterize the function of AT2 
oligomers, the current study reconstituted the 
two-step formation of AT2 receptor oligomers 
in vitro in a transfected cell system. The in 
vitro experiments revealed that the initial 
oxidative cross-linking step accounting for the 
formation of AT2 receptor dimers targets 
specifically AT2 with its tyrosine residues at 
putative inter-receptor contact sites (18), 
because a mutated AT2 receptor lacking the 
tyrosines of the cytoplasmic loop connecting 
transmembrane helices III/IV was not cross-
linked by ROS. Oxidative cross-linking 
assembles AT2 receptors and thereby generates 
the target for the second transglutaminase-
mediated cross-linking step leading finally to 
AT2 tetramers/oligomers. Experimental 
evidence suggests that transglutaminase-
dependent cross-linking of oxidized AT2 
receptor dimers involves the carboxyl terminus 
of AT2, which is a putative contact site 
between receptor dimers according to the 
rhodopsin model (18). Both cross-linking steps 
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are a direct consequence of aggregated Aβ and 
the pathogenesis of AD: Oxidative cross-
linking is due to high levels of ROS triggered 
by aggregated Aβ (21). The second 
transglutaminase-mediated cross-linking step 
is also linked to Aβ and the pathogenesis of 
AD, because cerebral microinjection of Aβ or 
enhanced formation of (aggregated) Aβ 
triggered the activation/induction of 
transglutaminase in mice (see first 
manuscript). In aggreement with a role of Aβ 
in inducing transglutaminase is the observation 
that transglutaminase activity is elevated in 
brain of AD patients (22,23). 
The Aβ-induced non-dissociable 
oligomeric AT2 receptor assembly seems to 
constitute a cellular platform that is kinetically 
favored to interact with activated Gαq/11 
proteins. The large interface of non-dissociable 
AT2 receptor oligomers could impede the rapid 
dissociation of activated Gαq/11 proteins upon 
binding. As a consequence, the activated 
Gαq/11 proteins are sequestered and arrested 
leading to decreased receptor-stimulated 
signaling. Mediating Gαq/11 arrest, the cross-
linked AT2 oligomers may thus contribute to 
the well-known Gαq/11 dysfunction in AD. 
 Our results suggest that the Gαq/11-
protein defect in brain of AD patients also has 
a pathophysiological role: (i) The G-protein 
defect mediated by AT2 oligomers is causally 
linked to the pathogenesis of AD because it 
relies on aggregated Aβ-induced ROS and 
transglutaminase. (ii) The induction of AT2 
oligomers by aggregated Aβ was accompanied 
by hippocampal neurodegeneration, tau 
phosphorylation and neuronal loss (see first 
manuscript). (iii) Stereotactic inhibition of 
cross-linked AT2 oligomers by expression of a 
mutated AT2 receptor retarded hippocampal 
Gαq/11 dysfunction, and symptoms of 
hippocampal neurodegeneration. 
 Neurodegeneration and compromised 
neurite integrity may be a direct consequence 
of the AT2 oligomer-induced Gαq/11 
sequestration as evidenced with hippocampal 
neurons from brains lacking Gαq/11 (7,24). 
Specifically, intact Gαq/11-mediated signaling 
protects (hippocampal) neurons from G12/13-
induced neurite damage (24,25). Since G12/13-
dependent signaling also links microtubules 
and microfilaments disorganization with tau 
phosphorylation (25), the AT2-mediated Gαq/11 
impairment is likely to induce symptoms of 
neurodegeneration and increased phospho-tau 
levels via an enhanced activation of the G12/13 
pathway.  
 Altogether, Gαq/11-inhibitory AT2 
receptor oligomers are formed by two 
sequential cross-linking steps triggered by 
(aggregated) Aβ. Dominant-negative AT2 
oligomers may reflect the process of ongoing 
Aβ-induced neurodegeneration, and also 
actively contribute to neuron damage.  
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FOOTNOTES 
 
*The abbreviations used are: AD, Alzheimer`s Disease; Aβ, amyloid β; HEK cells, human 
embryonic kidney cells; ROS, reactive oxygen species; APPSw mice, transgenic mice expressing 
human APP695 with the double mutation (K670N, M671L), which was identified in a Swedish 
family with early onset Alzheimer`s disease. 
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The initial characterization of AT2 receptor oligomers in vivo is presented in the accompanying 
(first) manuscript entitled "Angiotensin II AT2 receptor oligomers mediate G-protein dysfunction 
in an animal model of Alzheimers`s disease".  
 
 
FIGURE LEGENDS 
 
Fig. 1. Oxidative and transglutaminase-mediated cross-linking of AT2 receptors in vitro. 
A & B. Immunoblot of AT2 receptors detected with affinity-purified F(ab)2 fragments of 
AT2-specific antibodies pre-absorbed to human proteins (IB: anti-AT2) on membranes of 
HEK cells expressing wild-type AT2 receptor (A) or mutated AT2TyrAla143,148,162 (B). 
ROS was induced by expression of NOX-3. As indicated, pretreatment with the 
antioxidant diferuloylmethane (±Antiox., 40 µM) was performed. Arrowheads mark 
monomeric (M), dimeric (D) and oligomeric (O) AT2 receptor. C & D. Immunoblot of 
AT2 receptors (IB: anti-AT2) on membranes of HEK cells expressing wild-type AT2 
receptor (AT2; C) or AT21-325 (AT2ΔCTer; D). ROS was induced in HEK cells by co-
transfection of NOX-3 in cells expressing activated transglutaminase-2 (NOX-3/Tg). As 
indicated, cells were treated with the transglutaminase inhibitor monodansyl cadaverine 
(Tg-inhib.; 200 µM). E. The AT1 receptor is not significantly cross-linked by 
ROS/transglutaminase (NOX-3/Tg) as revealed by immunblotting of AT1 receptors (IB: 
anti-AT1) on membranes of HEK cells expressing wild-type AT1 receptor. As indicated, 
cells were treated with the transglutaminase inhibitor monodansyl cadaverine (Tg-inhib.; 
200 µM) or the antioxidant diferuloylmethane (±Antiox., 40 µM). F. Chimeric 
AT2/AT1COO- receptor is not a target of transglutaminase-2. ROS was induced in HEK 
cells by co-transfection of NOX-3 in cells expressing activated transglutaminase-2 
(NOX-3/Tg). As indicated, cells were treated with the transglutaminase inhibitor 
monodansyl cadaverine (Tg-inhib.). 
 
Fig. 2. AT2 receptor oligomers sequester Gαq/11 in vitro. A. Wild-type AT2 receptors were 
expressed in HEK cells under basal conditions yielding dissociable AT2 receptors (lanes 
1,3) or upon ROS generation by NOX-3 in cells expressing activated transglutaminase-2 
to form cross-linked AT2 oligomers (lanes 2,4, NOX-3/Tg). The left panel (lanes 1,2) 
shows an immunoblot of AT2 receptors with cell membranes (IB: anti-AT2). The right 
panel shows an immunoblot of AT2 receptors co-enriched with Gαq/11 from solubilized 
membranes subjected to immuno-affinity purification of Gαq/11 (AP: anti-q/11; IB: anti-
AT2) (upper blot). The lower panel shows a control immunoblot demonstrating equal 
enrichment of Gαq/11 (AP/IB: anti-q/11). B. The reciprocal experiment confirmed that 
Gαq/11 was not significantly co-enriched with AT2 receptors under basal conditions (lane 
1) whereas upon induction of AT2 oligomers by NOX-3/Tg, AT2 interacted with Gαq/11 
(lane 2) as determined by immuno-affinity enrichment of AT2 and immunoblot detection 
of co-enriched Gαq/11 (AP: anti-AT2; IB: anti-q/11). The right panel (lanes 3,4) shows 
equal enrichment of AT2 receptors under both conditions (AP/IB: anti-AT2). C. AT2 
oligomers (± AT2olig; ~ 150 fmol/mg) suppress the carbachol-stimulated (±Cch) 
interaction of M1 receptors with Gαq as determined by immuno-affinity enrichment of M1 
receptors from M1-transfected HEK cells, and detection of co-enriched Gαq (AP: anti-
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M1; IB: anti-Gαq). The lower panel shows equal enrichment of M1 receptors (AP/IB: 
anti-M1). D & E. Carbachol-stimulated M1-Gαq interaction in the presence of increasing 
levels of oligomeric AT2 (AT2olig; +NOX-3/Tg; D) or mutated AT2ΔCTer receptors 
(AT2ΔCTer; +NOX-3/Tg; E). The Gαq bound to the affinity-purified M1 receptor from 
solubilized HEK cell membranes was quantified by [125I]-labeled F(ab)2 fragments of 
anti-Gαq antibodies added to the affinity matrix. Data represent mean ± s.e.m., n=3, (*P < 
0.001 versus column 0, i. e. the stimulated Gαq/M1 interaction of HEK cells expressing 
only M1, ANOVA followed by Dunnett`s multiple comparison test). The insets show 
representative immunoblots of the eluates detecting (i) Gαq co-enriched with stimulated 
M1 (upper panels; AP: anti-M1, IB: anti-Gαq), and (ii) enriched M1 (lower panels; AP/IB: 
anti-M1). 
 
Fig. 3. Gαq/11-sequestering AT2 receptor oligomers inhibit basal and carbachol-stimulated 
activation of Gαq/11. A & B. Activation of Gαq/11 as determined by basal (columns 1,2) 
and carbachol-stimulated (+Cch; columns 3,4) [35S]GTPγS binding followed by immuno-
affinity enrichment of Gαq/11 with membranes of M1 receptor-expressing HEK cells 
(~900 fmol/mg) co-expressing ~150 fmol/mg protein of AT2 (A) or AT2ΔCTer (B). As 
indicated, [35S]GTPγS binding was determined with membranes of cells co-expressing 
NOX-3 and activated transglutaminase-2 (±NOX-3/Tg). Data represent mean ± s.e.m., 
n=6 (*P < 0.0001). 
 
Fig. 4. AT2 receptor oligomers suppress Gαq/11-stimulated signaling. A. Inositol 
phosphate signal of M1-receptor-expressing HEK cells co-expressing dissociable AT2 
receptors (+AT2mono) or cross-linked AT2 receptor oligomers (+AT2olig). Total cellular 
inositol phosphate levels were determined under basal conditions (-), upon stimulation 
with carbachol (Cch, 100 µM), GTPγS (100 µM in a nominally Ca2+-free 
permeabilization buffer containing 10 µM digitonin), AlF4- (300 µM), Ca2+ (10 µM in 
permeabilization buffer) or upon expression of the constitutively activated Gα11Q209L 
mutant. Data are the mean ± s.e.m., n=6 (*P < 0.0002). B. Concentration response 
relationship of the carbachol-stimulated inositol phosphate signal of M1 receptor-
expressing HEK cells co-expressing dissociable AT2 receptors (+AT2mono) or AT2 
receptor oligomers (+AT2olig). Inositol phosphates are expressed as % of maximum 
stimulation, i. e. the signal obtained with 100 µM carbachol on cells with dissociable AT2 
receptors (12,710 ± 420 d.p.m.). Data represent mean ± s.d., n=3. C. Carbachol-
stimulated (Cch; 100 µM) rise in the free intracellular calcium concentration, [Ca2+]i, of 
M1 receptor-expressing HEK cells co-expressing dissociable AT2 (+AT2mono; panels 1-3) 
or AT2 oligomers (+AT2olig; panels 4-6). As indicated, cells were co-stimulated with 100 
nM of angiotensin II (Ang, panels 2,5). In the experiments of panels 3 and 6, cells were 
desensitized by prior stimulation with carbachol for 30 min at 37°C followed by washing 
steps (Cch desens.). Single experiments are representative of three independent 
experiments, each with similar results. D. Fluorescence-activated cell sorting analysis 
(FACS) of cell-surface M1 receptors of HEK cells co-expressing dissociable AT2 
receptors (+AT2mono; panels 1,3) or AT2 oligomers (+AT2olig; panels 2,4). In the 
experiments of panels 3 and 4, M1 receptor redistribution (Redistrib.) was induced by 
stimulation with 1 mM carbachol for 60 min at 37 °C. Cell-surface M1 receptors were 
determined by FACS using affinity-purified F(ab)2 fragments of M1-specific antibodies. 
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Fig. 5. AT2ΔCTer suppresses AT2 oligomerization in vitro. A. Immunoblot of wild-type 
AT2 receptors (IB: anti-AT2CTer; ~ 150 fmol/mg) expressed in HEK cells upon ROS 
generation by NOX-3 and transglutaminase-2 activation (NOX-3/Tg) in the absence (-) 
or presence (+) of AT2ΔCTer suppressing the formation of cross-linked AT2 oligomers 
(lane 2 versus 1). The applied antibodies were raised against a carboxyl terminal epitope 
of AT2 that is lacking in AT2ΔCTer, and cross-react specifically with wild-type AT2. B. 
Effective Gαq/11 activation (Basal - columns 1,2; +Cch - columns 3,4) upon inhibition of 
AT2 oligomerization by AT2ΔCTer. Activation of Gαq/11 was determined in the presence of 
NOX-3 and activated transglutaminase-2 (NOX-3/Tg) with membranes of M1 receptor-
expressing HEK cells co-expressing ~150 fmol/mg protein of AT2 in the absence (-) or 
presence (+) of AT2ΔCTer (~ 150 fmol/mg protein). Data represent mean ± s.e.m., n=6 (*P 
< 0.001). 
 
Fig. 6. Inhibition of AT2 oligomerization slows progression of neurodegeneration in "AD 
mice". A. Immunoblot of hippocampal AT2 receptors of four stressed APPSw mice upon 
stereotactic injection of a lentivirus encoding AT2ΔCTer (Treated) revealed decreased AT2 
receptor oligomerization compared to mice injected with a control lentivirus (Control). 
Applied antibodies cross-react with a C-terminal epitope of AT2 that is lacking in 
AT2ΔCTer (IB: anti-AT2CTer). B. Immunohistochemistry applying antibodies cross-reacting 
with an N-terminal epitope of AT2 (anti-AT2NTer) to visualize AT2 and AT2ΔCTer revealed 
AT2 receptor expression in CA1 neuronal cell bodies and largely intact dendrites of 
stressed APPSw transgenic mice co-expressing AT2ΔCTer (Treated) compared to mice 
receiving injection of a control lentivirus (Control) encoding β-galactosidase (original 
magnification x 300). C. Inhibition of AT2 oligomerization by AT2ΔCter retarded the 
development of symptoms of dendritic degeneration in the injected CA1 area of stressed 
APPSw transgenic mice (Treated) compared to mice injected with a control lentivirus 
(Control) as determined by immunohistochemistry with anti-MAP2 antibodies (original 
magnification x 300). D. DNA strand breaks were barely detectable in the injected CA1 
area of stressed APPSw mice upon inhibition of AT2 oligomerization by AT2ΔCTer 
(Treated) compared to stressed APPSw mice injected with a control lentivirus (Control) as 
determined by in situ TUNEL labeling (original magnification x 300). E. Inhibition of 
AT2 oligomerization in the CA1 area of stressed APPSw transgenic mice by AT2ΔCTer 
(Treated) led to a significantly decreased hippocampal transglutaminase activity 
compared to stressed APPSw transgenic mice injected with a control lentivirus (Control). 
Data represent mean ± s.e.m., n=8 (*P < 0.01). F & G. Inhibition of AT2 oligomerization 
by AT2ΔCTer (Treated) led to a significantly better performance of stressed APPSw 
transgenic mice of the water maze acquisition (F) and retention (G) test compared to mice 
injected with a control lentivirus (Control). Data represent mean ± s.e.m., n = 12 mice per 
subgroup (F: *P < 0.05; **P < 0.008; G: *P < 0.003; ANOVA with Dunn`s multiple 
comparison test).  
 
Fig. 7. Inhibition of AT2 oligomerization prevents G-protein dysfunction in "AD mice". 
A. Immunohistochemistry with antibodies cross-reacting with an N-terminal epitope of 
AT2 (anti-AT2NTer) revealed dendritic pathology of CA1 neurons of stressed APPSw mice 
receiving stereotactic injection of a lentivirus encoding wild-type AT2 receptor (+AT2) 
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compared to largely intact dendrites of mice expressing AT2ΔCTer (+AT2ΔCTer; 
magnification x 300). B. Strongly impaired basal and M1 receptor-stimulated (Cch) 
activation of Gαq/11 in the hippocampus of stressed APPSw mice injected with a lentivirus 
encoding AT2 (+AT2) compared to the activation of Gαq/11 in mice expressing AT2ΔCTer 
(+AT2ΔCTer). Data are from four mice/group (± s.e.m.; *P < 0.02; **P < 0.001). C. 
Reduced activity of hippocampal α-secretase of stressed APPSw mice injected with a 
lentivirus encoding AT2 (+AT2) compared to the unimpaired α-secretase activity of mice 
expressing AT2ΔCTer (+AT2ΔCTer). Data are given as percentage of control, i. e. the α-
secretase activity of non-stressed APPSw mice receiving injection of a control lentivirus 
(i. e. 100 %) and represent mean ± s.e.m., n=4 (*P < 0.01). 
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